RE:RE:RE:Food for Thought?Lots of info to take in. As for the sentiment TRX sold cheap, this may be true when you place TRX into a bubble, but we have to look at Aralez, Yospralla, and the 350 million capital promised to be injected into the new Irish based company. So, what you're looking at is the 25% premium + how valuable will the 33% investment in this new company be? I don't know the answer to that, but Harris and Company are not idiots, so I can only assume their current assessment is that the positives that came with Pozen acquisition outweighed the 25% premium paid on the current value of the company. Given the 350 million investment and the Irish tax ramifications, God knows what's coming. They could be positioning themselves for a double takeout or a ride on a much more profitable drug pipeline than what they could generate on their own. Gottta do some diligence heree. These are just first thoughts. Gonna be reading a lot tonight! GLTA!